Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines

References

• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi:10.1111/all.13397
   PubMed Web of Science ®Google Scholar
• Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866–1874. doi:10.1016/j.jaip.2020.03.030
   PubMed Web of Science ®Google Scholar
• Fricke J, Ávila G, Keller T, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi:10.1111/all.14037
   PubMed Web of Science ®Google Scholar
• Goldstein S, Gabriel S, Kianifard F, Ortiz B, Skoner DP. Clinical features of adolescents with chronic idiopathic or spontaneous urticaria: review of omalizumab clinical trials. Ann Allergy Asthma Immunol. 2017;118(4):500–504. doi:10.1016/j.anai.2017.02.003
   PubMed Web of Science ®Google Scholar
• Curto-Barredo L, Pujol RM, Roura-Vives G, Gimenez-Arnau AM. Chronic urticaria phenotypes: clinical differences regarding triggers, activity, prognosis and therapeutic response. Eur J Dermatol. 2019;29(6):627–635. doi:10.1684/ejd.2019.3674
   PubMed Web of Science ®Google Scholar
• Netchiporouk E, Sasseville D, Moreau L, Habel Y, Rahme E, Ben-Shoshan M. Evaluating comorbidities, natural history, and predictors of early resolution in a cohort of children with chronic urticaria. JAMA Dermatol. 2017;153(12):1236–1242. doi:10.1001/jamadermatol.2017.3182
   PubMed Web of Science ®Google Scholar
• Fernando S, Broadfoot A. Chronic urticaria–assessment and treatment. Aust Fam Physician. 2010;39(3):135–138.
   Google Scholar
• Cornillier H, Giraudeau B, Munck S, et al. Chronic spontaneous urticaria in children - a systematic review on interventions and comorbidities. Pediatr Allergy Immunol. 2018;29(3):303–310. doi:10.1111/pai.12870
   PubMed Web of Science ®Google Scholar
• Williams PV. Pharmacologic management of chronic urticaria in pediatric patients: the gap between guidelines and practice. Paediatr Drugs. 2020;22(1):21–28. doi:10.1007/s40272-019-00365-3
   PubMed Web of Science ®Google Scholar
• Sahiner UM, Civelek E, Tuncer A, et al. Chronic urticaria: etiology and natural course in children. Int Arch Allergy Immunol. 2011;156(2):224–230. doi:10.1159/000322349
   PubMed Web of Science ®Google Scholar
• Caffarelli C, Cuomo B, Cardinale F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. Acta Derm Venereol. 2013;93(3):268–272. doi:10.2340/00015555-1511
   PubMed Web of Science ®Google Scholar
• Bracken SJ, Abraham S, MacLeod AS. Autoimmune theories of chronic spontaneous urticaria. Front Immunol. 2019;10:627. doi:10.3389/fimmu.2019.00627
   PubMed Web of Science ®Google Scholar
• Altman K, Chang C. Pathogenic intracellular and autoimmune mechanisms in urticaria and angioedema. Clin Rev Allergy Immunol. 2013;45(1):47–62. doi:10.1007/s12016-012-8326-y
   PubMed Web of Science ®Google Scholar
• Du Toit G, Prescott R, Lawrence P, et al. Autoantibodies to the high-affinity IgE receptor in children with chronic urticaria. Ann Allergy Asthma Immunol. 2006;96(2):341–344. doi:10.1016/S1081-1206(10)61245-8
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017;72(10):1440–1460. doi:10.1111/all.13182
   PubMed Web of Science ®Google Scholar
• Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–882. doi:10.1016/j.jaci.2017.10.035
   PubMed Web of Science ®Google Scholar
• Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: what we know and what we do not know. J Allergy Clin Immunol. 2017;139(6):1772–1781 e1771. doi:10.1016/j.jaci.2016.08.050
   PubMed Web of Science ®Google Scholar
• Asero R, Marzano AV, Ferrucci S, Lorini M, Carbonelli V, Cugno M. Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria. Clin Exp Immunol. 2020;200(3):242–249. doi:10.1111/cei.13428
   Web of Science ®Google Scholar
• Altrichter S, Zampeli V, Ellrich A, Zhang K, Church MK, Maurer M. IgM and IgA in addition to IgG autoantibodies against FcɛRIα are frequent and associated with disease markers of chronic spontaneous urticaria. Allergy. 2020;75(12):3208–3215. doi:10.1111/all.14412
   PubMed Web of Science ®Google Scholar
• Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–1277. doi:10.1016/j.jaci.2014.02.036
   PubMed Web of Science ®Google Scholar
• Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185–1190.e1181. doi:10.1016/j.jaip.2017.10.001
   Web of Science ®Google Scholar
• Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365–1372, 1372.e1361–1366. doi:10.1016/j.jaci.2013.12.1076
   PubMed Web of Science ®Google Scholar
• Stull D, McBride D, Tian H, et al. Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria. Br J Dermatol. 2017;177(4):1093–1101. doi:10.1111/bjd.15454
   Web of Science ®Google Scholar
• Tondury B, Muehleisen B, Ballmer-Weber BK, et al. The pictorial representation of illness and self measure (PRISM) instrument reveals a high burden of suffering in patients with chronic urticaria. J Investig Allergol Clin Immunol. 2011;21(2):93–100.
   PubMed Web of Science ®Google Scholar
• Ferrer M. Epidemiology, healthcare, resources, use and clinical features of different types of urticaria. Alergologica 2005. J Investig Allergol Clin Immunol. 2009;19(Suppl 2):21–26.
   PubMed Web of Science ®Google Scholar
• Hergüner S, Kiliç G, Karakoç S, Tamay Z, Tüzün U, Güler N. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol. 2011;164(6):1342–1347. doi:10.1111/j.1365-2133.2010.10138.x
   Web of Science ®Google Scholar
• Gabrielli S, Le M, Netchiporouk E, et al. Chronic urticaria in children can be controlled effectively with updosing second-generation antihistamines. J Am Acad Dermatol. 2020;82(6):1535–1537. doi:10.1016/j.jaad.2020.02.041
   Web of Science ®Google Scholar
• Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2–12. doi:10.1016/j.anai.2019.08.014
   PubMed Web of Science ®Google Scholar
• Chipps BE, Lanier B, Milgrom H, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–1444. doi:10.1016/j.jaci.2017.03.002
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459–466. doi:10.1111/j.1398-9995.2009.02325.x
   PubMed Web of Science ®Google Scholar
• Simons FE, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol. 2011;128(6):1139–1150.e1134. doi:10.1016/j.jaci.2011.09.005
   PubMed Web of Science ®Google Scholar
• Kalpaklioglu F, Baccioglu A. Efficacy and safety of H1-antihistamines: an update. Antiinflamm Antiallergy Agents Med Chem. 2012;11(3):230–237. doi:10.2174/1871523011202030230
   PubMedGoogle Scholar
• Simons FE. H1-antihistamines in children. Clin Allergy Immunol. 2002;17:437–464.
   PubMedGoogle Scholar
• Fitzsimons R, van der Poel LA, Thornhill W, Du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122–131. doi:10.1136/archdischild-2013-304446
   PubMed Web of Science ®Google Scholar
• Wood RA, Khan DA, Lang DM, et al. American academy of allergy, asthma and immunology response to the EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of Urticaria 2017 revision. Allergy. 2019;74(2):411–413. doi:10.1111/all.13636
   PubMed Web of Science ®Google Scholar
• Bolognia J, Schaffer JV, Cerroni L. Dermatology. 4th rev. ed. Philadelphia: Elsevier; 2018. 2880p.
   Google Scholar
• Palmer RB, Reynolds KM, Banner W, et al. Adverse events associated with diphenhydramine in children, 2008–2015. Clin Toxicol (Phila). 2020;58(2):99–106. doi:10.1080/15563650.2019.1609683
   PubMed Web of Science ®Google Scholar
• De Bruyne P, Christiaens T, Boussery K, Mehuys E, Van Winckel M. Are antihistamines effective in children? A review of the evidence. Arch Dis Child. 2017;102(1):56–60. doi:10.1136/archdischild-2015-310416
   Web of Science ®Google Scholar
• Simons FE, Simons KJ. H1 antihistamines: current status and future directions. World Allergy Organ J. 2008;1(9):145–155. doi:10.1097/WOX.0b013e318186fb3a
   PubMedGoogle Scholar
• Yanai K, Yoshikawa T, Yanai A, et al. The clinical pharmacology of non-sedating antihistamines. Pharmacol Ther. 2017;178:148–156. doi:10.1016/j.pharmthera.2017.04.004
   PubMed Web of Science ®Google Scholar
• Bosma R, van den Bor J, Vischer HF, Labeaga L, Leurs R. The long duration of action of the second generation antihistamine bilastine coincides with its long residence time at the histamine H(1) receptor. Eur J Pharmacol. 2018;838:107–111. doi:10.1016/j.ejphar.2018.09.011
   Web of Science ®Google Scholar
• Wolverton SE. Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print. Elsevier Health Sciences; 2012.
   Google Scholar
• La Rosa M, Leonardi S, Marchese G, et al. Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children. Ann Allergy Asthma Immunol. 2001;87(1):48–53. doi:10.1016/S1081-1206(10)62322-8
   PubMed Web of Science ®Google Scholar
• Potter P, Mitha E, Barkai L, et al. Rupatadine is effective in the treatment of chronic spontaneous urticaria in children aged 2–11 years. Pediatr Allergy Immunol. 2016;27(1):55–61. doi:10.1111/pai.12460
   PubMed Web of Science ®Google Scholar
• Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D. Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol. 2003;48(4):535–541. doi:10.1067/mjd.2003.143
   PubMed Web of Science ®Google Scholar
• Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol. 2001;40(1):72–76. doi:10.1046/j.1365-4362.2001.00186.x
   PubMed Web of Science ®Google Scholar
• Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662–669. doi:10.1016/S1081-1206(10)61325-7
   PubMed Web of Science ®Google Scholar
• Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010;31(4):290–295. doi:10.2500/aap.2010.31.3349
   Web of Science ®Google Scholar
• Novak Z, Yanez A, Kiss I, et al. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases. Pediatr Allergy Immunol. 2016;27(5):493–498. doi:10.1111/pai.12555
   PubMed Web of Science ®Google Scholar
• Hide M, Suzuki T, Tanaka A, Aoki H. Efficacy and safety of rupatadine in Japanese adult and adolescent patients with chronic spontaneous urticaria: A double-blind, randomized, multicenter, placebo-controlled clinical trial. Allergol Int. 2019;68(1):59–67. doi:10.1016/j.alit.2018.06.002
   PubMed Web of Science ®Google Scholar
• Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy. 2007;62(5):539–546. doi:10.1111/j.1398-9995.2007.01330.x
   PubMed Web of Science ®Google Scholar
• Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–522. doi:10.1016/S1081-1206(10)62515-X
   PubMed Web of Science ®Google Scholar
• Inc. NPC. Product Monograph - XOLAIR® (Omalizumab); 2015. Available from: https://www.novartis.ca/sites/www.novartis.ca/files/xolair_scrip_e.pdf. Accessed March 22, 2020.
   Google Scholar
• Netchiporouk E, Nguyen CH, Thuraisingham T, Jafarian F, Maurer M, Ben-Shoshan M. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. Pediatr Allergy Immunol. 2015;26(6):585–588. doi:10.1111/pai.12407
   PubMed Web of Science ®Google Scholar
• Poddighe D, Vangelista L. Effects of omalizumab on basophils: potential biomarkers in asthma and chronic spontaneous urticaria. Cell Immunol. 2020;358:104215. doi:10.1016/j.cellimm.2020.104215
   PubMed Web of Science ®Google Scholar
• Ari A, Levy Y, Segal N, et al. Efficacy of omalizumab treatment for pediatric chronic spontaneous urticaria: A multi-center retrospective case series. Pediatr Dermatol. 2020;37(6):1051–1054. doi:10.1111/pde.14360
   PubMed Web of Science ®Google Scholar
• Staubach P, Peveling-Oberhag A, Lang BM, Zimmer S, Sohn A, Mann C. Severe chronic spontaneous urticaria in children - treatment options according to the guidelines and beyond - a 10 years review. J Dermatolog Treat. 2020;1–4. doi:10.1080/09546634.2020.1782326
   Web of Science ®Google Scholar
• Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101–109. doi:10.1016/j.jaci.2013.05.013
   PubMed Web of Science ®Google Scholar
• Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924–935. doi:10.1056/NEJMoa1215372
   PubMed Web of Science ®Google Scholar
• Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135(1):67–75. doi:10.1038/jid.2014.306
   PubMed Web of Science ®Google Scholar
• Asero R, Casalone R, Iemoli E. Extraordinary response to omalizumab in a child with severe chronic urticaria. Eur Ann Allergy Clin Immunol. 2014;46(1):41–42.
   Google Scholar
• Parisi GF, Papale M, Tardino LG, et al. Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria. J Dermatolog Treat. 2018;29(sup4):10–11. doi:10.1080/09546634.2018.1551609
   PubMed Web of Science ®Google Scholar
• Porcaro F, Di Marco A, Cutrera R. Omalizumab in patient with aspirin exacerbated respiratory disease and chronic idiopathic urticaria. Pediatr Pulmonol. 2017;52(5):E26–E28. doi:10.1002/ppul.23615
   PubMed Web of Science ®Google Scholar
• Uysal P, Erge D. Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab. Turk Pediatri Ars. 2018;53(4):250–254. doi:10.5152/TurkPediatriArs.2016.4042
   Google Scholar
• Passanisi S, Arasi S, Caminiti L, Crisafulli G, Salzano G, Pajno GB. Omalizumab in children and adolescents with chronic spontaneous urticaria: case series and review of the literature. Dermatol Ther. 2020;33(4):e13489. doi:10.1111/dth.13489
   PubMed Web of Science ®Google Scholar
• Al-Shaikhly T, Rosenthal JA, Ayars AG, Petroni DH. Omalizumab for chronic urticaria in children younger than 12 years. Ann Allergy Asthma Immunol. 2019;123(2):208–210 e202. doi:10.1016/j.anai.2019.05.003
   PubMed Web of Science ®Google Scholar
• Sirufo MM, Ginaldi L, De Martinis M. Successful treatment with omalizumab in a child with asthma and urticaria: a clinical case report. Front Pediatr. 2019;7:213. doi:10.3389/fped.2019.00213
   Web of Science ®Google Scholar
• Jesenak M, Ciljakova M, Janickova M, Banovcin P. Omalizumab in an 8-year-old boy with diabetes mellitus and refractory chronic spontaneous urticaria. J Investig Allergol Clin Immunol. 2019;29(2):144–146. doi:10.18176/jiaci.0351
   Web of Science ®Google Scholar
• Ossorio-García L, Jiménez-Gallo D, Albarrán-Planelles C, Arjona-Aguilera C, Linares-Barrios M. Chronic spontaneous urticaria in an 8-year-old girl treated with omalizumab. Clin Exp Dermatol. 2016;41(8):929–930. doi:10.1111/ced.12922
   Web of Science ®Google Scholar
• Leonardi L, Uva A, Duse M. Chronic urticaria in a child affected by atopic dermatitis: effective treatment with omalizumab. J Dermatolog Treat. 2018;29(sup3):17–19. doi:10.1080/09546634.2018.1543844
   PubMed Web of Science ®Google Scholar
• Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2–3):119–125. doi:10.1016/S0162-3109(00)00192-2
   PubMed Web of Science ®Google Scholar
• Harrison CA, Bastan R, Peirce MJ, Munday MR, Peachell PT. Role of calcineurin in the regulation of human lung mast cell and basophil function by cyclosporine and FK506. Br J Pharmacol. 2007;150(4):509–518. doi:10.1038/sj.bjp.0707002
   Web of Science ®Google Scholar
• Grattan CEH, O’Donnell BF, Francis DM, et al. Randomized double-blind study of cyclosporin in chronic ‘idiopathic’ urticaria. Br J Dermatol. 2000;143(2):365–372. doi:10.1046/j.1365-2133.2000.03664.x
   PubMed Web of Science ®Google Scholar
• Marsland AM, Soundararajan S, Joseph K, Kaplan AP. Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria. Clin Exp Allergy. 2005;35(5):554–559.
   Web of Science ®Google Scholar
• Inc. NPC. Product Monograph - Neoral® and Sandimmune® (Cyclosporine); 2015. Available from: http://www.ask.novartispharma.ca/download.htm?res=neoral_scrip_e.pdf&resTitleId=691. Accessed August 22, 2020.
   Google Scholar
• Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta-analysis and systematic review. J Allergy Clin Immunol Pract. 2018;6(2):586–599. doi:10.1016/j.jaip.2017.07.017
   PubMed Web of Science ®Google Scholar
• Ryan C, Amor KT, Menter A. The use of cyclosporine in dermatology: part II. J Am Acad Dermatol. 2010;63(6):949–972; quiz 973–944. doi:10.1016/j.jaad.2010.02.062
   Web of Science ®Google Scholar
• Doshi DR, Weinberger MM. Experience with cyclosporine in children with chronic idiopathic urticaria. Pediatr Dermatol. 2009;26(4):409–413. doi:10.1111/j.1525-1470.2009.00869.x
   PubMed Web of Science ®Google Scholar
• Giuliodori K, Ganzetti G, Campanati A, Simonetti O, Marconi B, Offidani A. A non-responsive chronic autoimmune urticaria in a 12-year-old autistic girl treated with cyclosporin. J Eur Acad Dermatol Venereol. 2009;23(5):619–620. doi:10.1111/j.1468-3083.2008.02987.x
   Web of Science ®Google Scholar
• Neverman L, Weinberger M. Treatment of chronic urticaria in children with antihistamines and cyclosporine. J Allergy Clin Immunol Pract. 2014;2(4):434–438. doi:10.1016/j.jaip.2014.04.011
   PubMed Web of Science ®Google Scholar
• Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20(5):386–390.
   PubMed Web of Science ®Google Scholar
• Ledford D, Broder MS, Antonova E, Omachi TA, Chang E, Luskin A. Corticosteroid-related toxicity in patients with chronic idiopathic urticariachronic spontaneous urticaria. Allergy Asthma Proc. 2016;37(6):458–465. doi:10.2500/aap.2016.37.3999
   Web of Science ®Google Scholar
• Balp MM, Weller K, Carboni V, et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. 2018;29(6):630–636. doi:10.1111/pai.12910
   PubMed Web of Science ®Google Scholar
• Poddighe D, Brambilla I, Licari A, Marseglia GL. Paediatric severe chronic spontaneous urticaria: successful management through conventional drug therapy. BMJ Case Rep. 2019;12(8):e230925. doi:10.1136/bcr-2019-230925
   Google Scholar
• Normansell R, Kew KM, Mansour G. Different oral corticosteroid regimens for acute asthma. Cochrane Database Syst Rev. 2016;5:Cd011801.
   Google Scholar
• De Filippo M, Clark E, Fillard A, Diaferio L, Caimmi D. Oral corticosteroids and asthma in children: practical considerations. Pediatr Allergy Immunol. 2020;31(Suppl 24):43–45. doi:10.1111/pai.13151
   Web of Science ®Google Scholar
• Donatti TL, Koch VH, Takayama L, Pereira RM. Effects of glucocorticoids on growth and bone mineralization. J Pediatr (Rio J). 2011;87(1):4–12. doi:10.1590/S0021-75572011000100002
   Web of Science ®Google Scholar
• McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol. 2008;20(2):131–137. doi:10.1097/BOR.0b013e3282f51031
   PubMed Web of Science ®Google Scholar
• Gabrielli S, Le M, Netchiporouk E, et al. Reply to “Comment on: ‘Children with chronic urticaria can be effectively controlled with updosing second-generation antihistamines’”. J Am Acad Dermatol. 2020;83(5):e365–e366. doi:10.1016/j.jaad.2020.06.997
   Web of Science ®Google Scholar
• Wedi B, Novacovic V, Koerner M, Kapp A. Chronic urticaria serum induces histamine release, leukotriene production, and basophil CD63 surface expression–inhibitory effects of anti-inflammatory drugs. J Allergy Clin Immunol. 2000;105(3):552–560. doi:10.1067/mai.2000.104939
   Web of Science ®Google Scholar
• Bisgaard H. Vascular effects of leukotriene D4 in human skin. J Invest Dermatol. 1987;88(2):109–114. doi:10.1111/1523-1747.ep12525225
   Web of Science ®Google Scholar
• Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113(1):134–140. doi:10.1016/j.jaci.2003.10.002
   PubMed Web of Science ®Google Scholar
• Di Lorenzo G, Pacor ML, Mansueto P, et al. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol. 2006;31(3):327–334. doi:10.1111/j.1365-2230.2006.02127.x
   Web of Science ®Google Scholar
• McBayne TO, Siddall OM. Montelukast treatment of urticaria. Ann Pharmacother. 2006;40(5):939–942. doi:10.1345/aph.1G006
   PubMed Web of Science ®Google Scholar
• de Silva NL, Damayanthi H, Rajapakse AC, Rodrigo C, Rajapakse S. Leukotriene receptor antagonists for chronic urticaria: a systematic review. Allergy Asthma Clin Immunol. 2014;10(1):24. doi:10.1186/1710-1492-10-24
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Skoner D, Boza ML, et al. Safety and tolerability of montelukast in placebo-controlled pediatric studies and their open-label extensions. Pediatr Pulmonol. 2009;44(6):568–579. doi:10.1002/ppul.21018
   PubMed Web of Science ®Google Scholar
• Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014;8:839–850. doi:10.2147/DDDT.S39100
   PubMed Web of Science ®Google Scholar
• Accolate [package insert]. Wilmington, DE: AstraZeneca; November 2013.
   Google Scholar
• Singulair (montelukast) [prescribing information]. Whitehouse Station, NJ: Merck and Co, Inc; April 2020.
   Google Scholar
• Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745. doi:10.1136/annrheumdis-2019-215089
   PubMed Web of Science ®Google Scholar
• Fiehn C, Ness T, Weseloh C, et al. Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol. 2020. doi:10.1007/s00393-020-00785-4
   Web of Science ®Google Scholar
• Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: a retrospective study. Arch Dermatol. 2005;141(7):855–859. doi:10.1001/archderm.141.7.855
   Google Scholar
• Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312(3):249–258. doi:10.1001/jama.2014.7682
   PubMed Web of Science ®Google Scholar
• Fernandez AP. Updated recommendations on the use of hydroxychloroquine in dermatologic practice. J Am Acad Dermatol. 2017;76(6):1176–1182. doi:10.1016/j.jaad.2017.01.012
   Web of Science ®Google Scholar
• Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–166. doi:10.1038/s41584-020-0372-x
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogué B, Leroux G, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317–326. doi:10.1007/s12016-015-8469-8
   PubMed Web of Science ®Google Scholar
• Lebin JA, LeSaint KT. Brief review of chloroquine and hydroxychloroquine toxicity and management. West J Emerg Med. 2020;21(4):760–763. doi:10.5811/westjem.2020.5.47810
   PubMed Web of Science ®Google Scholar
• Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–1394. doi:10.1016/j.ophtha.2016.01.058
   PubMed Web of Science ®Google Scholar
• Boonpiyathad T, Sangasapaviliya A. Hydroxychloroquine in the treatment of anti-histamine refractory chronic spontaneous urticaria, randomized single-blinded placebo-controlled trial and an open label comparison study. Eur Ann Allergy Clin Immunol. 2017;49(5):220–224. doi:10.23822/EurAnnACI.1764-1489.11
   Web of Science ®Google Scholar
• Iweala OI, Copenhaver C, Wu EY, Moran TP. Hydroxychloroquine as a steroid-sparing agent in an infant with chronic urticaria. Ann Allergy Asthma Immunol. 2018;120(1):102–104. doi:10.1016/j.anai.2017.10.011
   Web of Science ®Google Scholar
• Oguz Topal I, Kocaturk E, Gungor S, Durmuscan M, Sucu V, Yıldırmak S. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? J Dermatolog Treat. 2016;27(2):163–166. doi:10.3109/09546634.2015.1079297
   PubMed Web of Science ®Google Scholar
• Yuan I, Katari P, Shaker M. Vitamin D treatment for chronic urticaria: a case report. J Med Case Rep. 2019;13(1):193. doi:10.1186/s13256-019-2121-9
   Google Scholar
• Khafagy NH, Salem SA, Ghaly EG. Comparative study of systemic psoralen and ultraviolet A and narrowband ultraviolet B in treatment of chronic urticaria. Photodermatol Photoimmunol Photomed. 2013;29(1):12–17. doi:10.1111/phpp.12008
   Web of Science ®Google Scholar
• Shi CR, Li YP, Luo YJ, et al. IgE-mediated allergy: a rare cause of chronic spontaneous urticarial with allergen-specific immunotherapy as treatment option - a systematic review with meta-analysis from China. J Eur Acad Dermatol Venereol. 2012;26(5):533–544. doi:10.1111/j.1468-3083.2011.04302.x
   Web of Science ®Google Scholar
• Maurer M, Giménez-Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria. N Engl J Med. 2019;381(14):1321–1332. doi:10.1056/NEJMoa1900408
   PubMed Web of Science ®Google Scholar
• Boubouka CD, Charissi C, Kouimintzis D, Kalogeromitros D, Stavropoulos PG, Katsarou A. Treatment of autoimmune urticaria with low-dose cyclosporin A: a one-year follow-up. Acta Derm Venereol. 2011;91(1):50–54. doi:10.2340/00015555-0939
   Web of Science ®Google Scholar
• Blake SC, Murrell DF. Monitoring trough levels in cyclosporine for atopic dermatitis: A systematic review. Pediatr Dermatol. 2019;36(6):843–853. doi:10.1111/pde.13999
   Web of Science ®Google Scholar
• Yee J, Orchard D. Monitoring recommendations for oral azathioprine, methotrexate and cyclosporin in a paediatric dermatology clinic and literature review. Australas J Dermatol. 2018;59(1):31–40. doi:10.1111/ajd.12526
   PubMed Web of Science ®Google Scholar
• Xolair (Omalizumab) [package insert]. Dorval, QC: Novartis Pharmaceuticals Canada Inc.; 2015.
   Google Scholar